Missing the Forest for the Weeds: Filling the Holes in Louisiana’s Medical Marijuana Statutes to Protect Employees by Briley, Catherine
Louisiana Law Review 
Volume 79 
Number 3 Spring 2019 Article 11 
4-30-2019 
Missing the Forest for the Weeds: Filling the Holes in Louisiana’s 
Medical Marijuana Statutes to Protect Employees 
Catherine Briley 
Follow this and additional works at: https://digitalcommons.law.lsu.edu/lalrev 
 Part of the Labor and Employment Law Commons 
Repository Citation 
Catherine Briley, Missing the Forest for the Weeds: Filling the Holes in Louisiana’s Medical Marijuana 
Statutes to Protect Employees, 79 La. L. Rev. (2019) 
Available at: https://digitalcommons.law.lsu.edu/lalrev/vol79/iss3/11 
This Comment is brought to you for free and open access by the Law Reviews and Journals at LSU Law Digital 
Commons. It has been accepted for inclusion in Louisiana Law Review by an authorized editor of LSU Law Digital 
Commons. For more information, please contact kreed25@lsu.edu. 
  
Missing the Forest for the Weeds: Filling the Holes in 
Louisiana’s Medical Marijuana Statutes to Protect 
Employees 
TABLE OF CONTENTS 
 Introduction .................................................................................. 874 
I. Regulation of Marijuana Possession and Use at the  
Federal and State Levels .............................................................. 878 
 A. Federal Prohibition of Marijuana ........................................... 878 
 B. State Decriminalization of Marijuana for 
Medical Purposes ................................................................... 880 
 C. Disparity in Federal and State Law Governing 
Marijuana Use ........................................................................ 881 
 1. Executive Agency Actions .............................................. 881 
 2. Congressional Budget Modifications .............................. 884 
II. The Conflict of Federal and State Marijuana Law 
in Employment Law ..................................................................... 885 
 A. The Lone Finding of Preemption: Emerald Steel .................. 886 
 B. The Significance of Statutory Language: Coats .................... 889 
 C. The Use of Broad Protection of Rights 
as a Bridge: Barbuto .............................................................. 890 
 D. The Creation of Private Rights of Action: Noffsinger ........... 892 
III. Louisiana’s Incomplete Medical Marijuana Statutes ................... 893 
IV. Finding a Way Through the Weeds .............................................. 893 
 A. Louisiana Should Adopt an Explicit Employment 
Anti-Discrimination Provision ............................................... 894 
 B. A Model Statutory Provision that Balances  
Employee and Employer Needs ............................................. 895 
 Conclusion .................................................................................... 896 
 





Imagine: a woman named Anne has been suffering from Crohn’s 
disease for several years.1 Her symptoms, including extreme abdominal 
pain and burning ulcers, make daily life difficult.2 She tries several types 
of medication without success until her doctor recommends3 that she use 
medical marijuana—a practice the Louisiana Legislature recently made 
legal.4 Anne finds that the use of medical marijuana significantly relieves 
her symptoms. 
Anne goes to work and informs the Human Resources department that 
she has begun to use medical marijuana per her doctor’s recommendation. 
She assures the Human Resources representative that she will not use 
medical marijuana on company property or while on the job and that she 
will not be impaired during the workday. The Human Resources 
representative tells Anne that since state law sanctions her marijuana use she 
will not face any repercussions.5 Within a few days, however, Anne’s 
employer forces her to take a drug test pursuant to the company’s random 
drug testing policy. Upon testing positive for marijuana use, Anne is 
terminated.6 
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 1. Anne is a fictional person introduced to relay a real shortcoming in 
Louisiana law. 
 2. See generally Crohn’s Disease, MAYO CLINIC (Aug. 7, 2017), https:// 
www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20 
353304 [https://perma.cc/YA2M-36AZ]. 
 3. See LA. REV. STAT. § 40:1046 (2018). Louisiana’s medical marijuana 
statutes use the term “recommend” rather than “prescribe” in order to protect 
doctors from violating the Controlled Substances Act, which forbids medical 
professionals from prescribing marijuana. 21 U.S.C. § 812(c)(10) (2012); see also 
James Gill, Lawmakers Play Word Games on Medical Marijuana, ADVOCATE 
(June 8, 2016, 5:13 PM), https://www.theadvocate.com/new_orleans/opinion 
/james_gill/article_3db8e178-7713-53ee-9453-dc15762924fc.html [https://perma 
.cc/CF85-AXCC]. 
 4. LA. REV. STAT. § 40:1046 (creating a method by which doctors are able 
to recommend medical marijuana to patients suffering from any of the debilitating 
illnesses specifically listed in the statute). 
 5. See id. § 40:966(I) (providing exemptions for arrest and prosecution to 
persons lawfully in possession of medical marijuana); see also id. § 
40:1046A(2)(a) (providing a plan for the production, cultivation, and distribution 
of medical marijuana and listing Crohn’s disease as a debilitating medical 
condition which medical marijuana can be recommended to treat). 
 6. See id. §§ 40:1001–05 (allowing employers to conduct random drug 
testing of employees as a condition of their employment). 




Following her termination, Anne discusses possible legal recourse 
with her lawyer for discrimination under the Americans with Disabilities 
Act of 1990 (“ADA”).7 The attorney informs Anne that the ADA provides 
no remedy because it specifically exempts individuals “currently engaging 
in the illegal use of drugs.”8 The use of marijuana is illegal under the 
federal Controlled Substances Act (“CSA”) even though Louisiana law 
allows for its medical use.9 Louisiana law allows a doctor to recommend 
medical marijuana to a patient for certain severe, debilitating medical 
conditions10 and allows a patient to use medical marijuana without fear of 
criminal prosecution,11 but the law does nothing to protect workers from 
discrimination based on their use of a state-sanctioned medicine.12 Anne’s 
attorney tells her the harsh reality she faces: the ADA does not protect her 
from discrimination based on her use of marijuana, and Louisiana law 
offers no solution either. Upon discovery of her lack of legal recourse, 
Anne is faced with her reality: no job and slim prospects for future 
employment unless she stops using medical marijuana to manage her 
painful condition.  
Although Anne’s situation is presently hypothetical, various Louisiana 
citizens will find themselves in her shoes if the legislature does not fill the 
existing gaps in Louisiana’s medical marijuana statutes.13 Louisiana is 
currently laying the groundwork for legal production and distribution of 
marijuana, and the producers that state legislators selected expect eligible 
patients to have access to the medicine in early 2019.14 The lack of 
                                                                                                             
 7. 42 U.S.C. §§ 12111–17. 
 8. Id. § 12114. 
 9. Id.; see also LA. REV. STAT. § 40:966(I) (providing exemptions for arrest 
and prosecution to persons lawfully in possession of medical marijuana); see also 
21 U.S.C. § 812(c)(10) (designating the statutorily defined “marihuana” as a 
Schedule I controlled substance). 
 10. LA REV. STAT. § 40:1046 (listing “cancer, positive status for human 
immunodeficiency virus, acquired immune deficiency syndrome, cachexia or 
wasting syndrome, seizure disorders, epilepsy, spasticity, Crohn’s disease, 
muscular dystrophy, or multiple sclerosis” as the qualifying debilitating medical 
conditions medical marijuana can be recommended to treat). 
 11. See id. § 40:966 (providing exemptions for arrest and prosecution to 
persons lawfully possessing medical marijuana). 
 12. See id.; see also id. § 40:1046 (lacking any protection against employment 
discrimination on the basis of medical marijuana use). 
 13. Id. 
 14. See Stephanie Riegel, Medical marijuana behind schedule, again, but 
program making progress, GREATER BATON ROUGE BUS. REP. (Aug. 29, 2018), 
https://www.businessreport.com/article/medical-marijuana-behind-schedule-pro  




employment protections is a gap in the statutory scheme that lawmakers 
must correct to ensure that no Louisiana citizen has to face an impossible 
choice between health and employment.  
Marijuana is a drug with a reputation because of its long illegality and 
psychoactive nature, and some argue that lawmakers should not grant legal 
protections to individuals who use the substance.15 The decriminalization 
of medical marijuana in Louisiana faced criticism, with skeptics claiming 
that de facto legalization of marijuana in any context encourages substance 
abuse.16 Others object to decriminalization because of the lack of research 
on marijuana’s efficacy as a therapeutic treatment and accuse the 
Louisiana Legislature of moving too fast when it decriminalized use of the 
plant for medical purposes.17 Substantial research has demonstrated, 
however, that marijuana can improve the symptoms of individuals 
suffering from illnesses such as cancer and Crohn’s disease.18 The research 
                                                                                                             
gram-making-progress [https://perma.cc/HFZ2-F6D3] (discussing delays in the 
production and distribution of the first crop of medical marijuana and its expected 
availability in early 2019).  
 15. See The Controlled Substances Act of 1970, 21 U.S.C. § 812 (2012); see 
also Robert L. DuPont, Marijuana Has Proven to Be a Gateway Drug, N.Y. TIMES 
(Apr. 26, 2016, 3:22 AM), https://www.nytimes.com/roomfordebate/2016/04/26/is-
marijuana-a-gateway-drug/marijuana-has-proven-to-be-a-gateway-drug [https://per 
ma.cc/8L75-ZE3U]. 
 16. See, e.g., Dean Robinson & A. Kennison Roy, ‘Medical’ marijuana bill 
will do more harm than good, professionals argue in guest column, ADVOCATE 
(May 10, 2016, 5:20 PM), https://www.theadvocate.com/baton_rouge/opinion 
/our_views/article_53552655-0124-5afe-8700-c0e1a23ab3ce.html [https://perma 
.cc/A3QD-ZNNT]; Ken Roy, Letter to the Editor, Jindal should veto medical 
marijuana bill, ADVOCATE (June 16, 2016, 2:02 PM), https://www.theadvocate 
.com/baton_rouge/opinion/letters/article_054147fd-cb46-53f9-a199-2fc0cb1c11ef 
.html [https://perma.cc/CV2E-MQAM]; Mike Stone & Michael A. Ranatza, 
Opinion, Louisiana Sheriffs’ Association leaders: Balance needed on medical 
marijuana, ADVOCATE (May 8, 2016, 11:36 AM), https://www.theadvocate.com 
/baton_rouge/opinion/our_views/article_3f4a5486-9285-5f4b-9095-28f2f25d617  
3.html [https://perma.cc/8VMP-CLHB]. 
 17. See, e.g., Robinson & Roy, supra note 16; Roy, supra note 16; Stone & 
Ranatza, supra note 16. 
 18. See Mary E. Lynch & Fiona Campbell, Cannabinoids for Treatment of 
Chronic Non-Cancer Pain; A Systematic Review of Randomized Trials, 72 BRIT. 
J. CLINICAL PHARMACOLOGY 735, 742 (2011) (finding that marijuana is a 
“modestly effective and safe treatment option for chronic non-cancer 
(predominantly neuropathic) pain”); see also Brenda E. Porter & Catherine 
Jacobson, Report of a Parent Survey of Cannabidiol-Enriched Cannabis Use in 
Pediatric Treatment-Resistant Epilepsy, 29 EPILEPSY & BEHAV. 574, 575 (2013) 
(finding that parents using marijuana to treat children's epilepsy report a “high 




demonstrating medical marijuana’s benefits, as well as Louisiana citizens’ 
personal testimony that medical marijuana alleviated symptoms, led 
Louisiana to decriminalize the substance for medical use.19 If Louisiana is 
willing to allow the use of marijuana therapeutically, it should not force 
citizens to choose between health and the ability to earn a living.  
This Comment recommends that the Louisiana Legislature fill the current 
gaps in medical marijuana legislation before marijuana is recommended for 
medical use in this state.20 The solution lies in amending Louisiana Revised 
Statutes § 40:1046 to include anti-discrimination protection from adverse 
employment action, as Connecticut, Arizona, and several other states have 
done in connection with the legalization of medical marijuana.21 The new anti-
discrimination provision should create a private cause of action for employees 
to sue their employers in the event that the employees are wrongfully 
terminated for their legal use of medical marijuana.22 
Part I of this Comment discusses the current status of marijuana 
legislation in the United States at both the federal and state levels. It 
provides a background on the tension between the federal CSA and state 
decriminalization efforts. Part II focuses on state medical marijuana 
statutes in the context of employment law, including significant court 
decisions either upholding or dismissing statutory protections from 
wrongful termination for marijuana use. Part III examines the current state 
of Louisiana’s medical marijuana statutes and analyzes their inability to 
                                                                                                             
rate of success in reducing seizure frequency with this treatment”); see also Jody 
Corey-Bloom et al., Smoked Cannabis for Spasticity in Multiple Sclerosis: A 
Randomized, Placebo-Controlled Trial, 184 CANADIAN MED. ASS’N J. 1143, 
1145 (2012) (administering marijuana to patients with multiple sclerosis and 
spasticity resulted in a “clinically meaningful” reduction in pain). 
 19. See The Advertiser, Editorial, Medical marijuana bill deserves support, 
ADVERTISER (May 26, 2015, 2:18 PM), http://www.theadvertiser.com/story/opin 
ion/2015/05/26/medical-marijuana-bill-deserves-support/27971151/ [https://per 
ma.cc/AYQ9-H77M]; Ken Stickney, How Louisiana’s medical marijuana bill has 
evolved, ADVERTISER (May 9, 2015, 11:06 PM); Kris Wartelle, Mother’s dying wish 
to legalize medical marijuana granted, ADVERTISER (June 11, 2015, 3:30 PM) 
http://www.theadvertiser.com/story/news/2015/06/11/womans-dying-wish-legal  
ize-medical-marijuana-granted/71074362/ [https://perma.cc/A597-85TL].  
 20. See Riegel, supra note 14. 
 21. See CONN. GEN. STAT. § 21a-408p(b) (2018); ARIZ. REV. STAT. § 36-
2813 (2018); DEL. CODE ANN. tit. 16, § 4905A (2018); 410 ILL. COMP. STAT. 
130/40 (2018); ME. REV. STAT. tit. 22, § 2423–E (2018); NEV. REV. STAT. § 
453A.800 (2018); N.Y. PUB. HEALTH LAW § 3369 (2018); MINN. STAT. § 152.32; 
R.I. GEN. LAWS § 21–28.6–4 (2018). 
 22. See generally Noffsinger v. SSC Niantic Operating Co. LLC, 273 F. 
Supp. 2d 326 (D. Conn. 2017). 




protect Louisiana employees who use medical marijuana pursuant to a 
doctor’s recommendation. Part IV proposes solutions, the best solution 
being a statutory provision creating a cause of action for employees to sue 
for wrongful termination under the statutes decriminalizing medical 
marijuana. This Comment concludes by emphasizing the need for 
Louisiana lawmakers to show foresight by protecting citizens whose state-
sanctioned medical marijuana use may threaten their livelihoods. 
I. REGULATION OF MARIJUANA POSSESSION AND USE AT THE FEDERAL 
AND STATE LEVELS 
Marijuana and all of its components and derivatives have been illegal 
under federal law since 1970.23 Thirty-three states, however, have 
decriminalized the possession and use of marijuana for medical 
purposes.24 The wholesale forbiddance of marijuana under federal law and 
the contrasting state law legalization of marijuana for particular purposes, 
namely medicinal use, have led to tension in the law. Questions regarding 
preemption and principles of federalism are central to marijuana 
legislation, as the answers to those questions determine whether states 
have the power to decriminalize medical marijuana or offer employment 
protection to marijuana users.25 
A. Federal Prohibition of Marijuana 
The CSA categorizes controlled substances into one of five Schedules 
based on the substance’s potential for abuse and potential medical uses.26 
The most severe classification under the CSA is Schedule I, since 
substances categorized as Schedule I drugs are those that Congress finds 
have the highest risk of abuse and no recognized medical use.27 In 1970, 
Congress designated marijuana and all of its components as Schedule I 
                                                                                                             
 23. See 21 U.S.C. § 812(c)(10) (2012). 
 24. State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (Nov. 
8, 2018), http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx 
[https://perma.cc/X6HG-PUM6]. 
 25. See Lea Brilmayer, A General Theory of Preemption: With Comments on 
Statement Decriminalization of Marijuana, 58 B.C. L. REV. 895 (2017); see also 
Erwin Chemerinsky et al., Cooperative Federalism and Marijuana Regulation, 
62 UCLA L. REV. 74 (2015). 
 26. 21 U.S.C. § 812. 
 27. Id. § 812(b)(1). 




controlled substances under the CSA.28 This classification placed 
marijuana in the same category as heroin, cocaine, and lysergic acid 
diethylamide.29 Marijuana’s classification as a Schedule I substance makes 
its cultivation, possession, and use for any purpose illegal under federal 
law.30 The penalties for violating the CSA’s prohibition of marijuana are 
significant, and the legality of the marijuana cultivation or possession 
under state law has no bearing on the federal law’s treatment of violators.31 
First-time possessors of marijuana face up to a year in prison and a $1,000 
fine, but even a small producer of marijuana plants faces up to five years 
in prison and a fine of up to $250,000.32 The CSA’s plain language would 
punish state-sanctioned users and producers of medical marijuana just as 
harshly as users and drug dealers whose activities are entirely illicit.33 
Contemporaries have questioned marijuana’s classification as a 
Schedule I substance since the passage of the CSA because of the drug’s 
potential medical benefits.34 Within two years of the CSA’s passage, a 
commission Congress created to research marijuana recommended the 
rescheduling and decriminalization of marijuana for medical research 
purposes.35 Later clinical studies in which the Food and Drug 
Administration approved of marijuana have proven what the commission 
found to be true at the outset of the CSA’s existence: marijuana has 
possible medical value and therefore should not be a Schedule I substance 
under the CSA.36 Studies demonstrating potential medical purposes for 
marijuana have had no effect on federal law.37 The federal government has 
not entirely ignored such medical studies, however, as the majority of state 
                                                                                                             
 28. See id. § 802(16) (defining marijuana as “all parts of the plant Cannabis 
sativa L.”); see also id. § 812(c)(10) (designating the statutorily defined 
“marijuana” as a Schedule I controlled substance). 
 29. See id. § 812. 
 30. Id. § 844(a). 
 31. See id. § 841 (giving the penalty guidelines for various types of CSA 
violations involving marijuana). 
 32. See id. (giving the penalties for a first-time possessor and a cultivator with 
less than 50 plants). 
 33. See id. (setting penalty guidelines with no distinctions for violators acting 
in accord with state law). 
 34. NAT’L COMM’N ON MARIJUANA AND DRUG ABUSE, MARIHUANA: A 
SIGNAL OF MISUNDERSTANDING (1972). 
 35. Id. 
 36. See supra note 18.  
 37. 21 U.S.C. § 844(a). 




governments have taken notice and started to decriminalize the use of 
medical marijuana.38 
B. State Decriminalization of Marijuana for Medical Purposes 
Although federal law recognizes no medical use for marijuana, the 
majority of states have created statutory schemes allowing access to 
marijuana or some of its derivatives—like cannabinoids and cannabis 
oil—for medical purposes.39 Despite lingering concerns about the 
potentially harmful effects of marijuana, state legislatures justify medical 
marijuana laws based on findings that patients can use medical marijuana 
to provide relief for conditions such as cachexia, cancer, glaucoma, AIDS, 
nausea, post-traumatic stress syndrome, severe pain, seizures, persistent 
muscle spasms, and multiple sclerosis.40 Marijuana is generally used to 
relieve pain, combat malnutrition and loss of appetite, and reduce 
muscular spasms or seizures.41 
All states with medical marijuana programs protect residents who 
qualify for treatment with medical marijuana from state criminal 
prosecution.42 Some states, such as Massachusetts and Michigan, grant 
even broader protections to protect medical marijuana patients from being 
denied any right or privilege based on their use of medical marijuana.43 
                                                                                                             
 38. See State Medical Marijuana Laws, supra note 24 (listing 33 states which 
allow for public medical marijuana programs and 18 states which allow use of 
low THC, high cannabidiol products for medical reasons). 
 39. Id. 
 40. See Oregon Medical Marijuana Program Statistics, OR. HEALTH AUTH., 
http://www.oregon.gov/oha/PH/DISEASESCONDITIONS/CHRONICDISEAS
E/MEDICALMARIJUANAPROGRAM/Documents/OMMP%20Statistic%20Sn
apshot%20-%2004-2017.pdf [https://perma.cc/ED87-LZVR] (last updated Apr. 
2017) (listing above diseases as covered under Oregon state medical marijuana law); 
see also LA. REV. STAT. § 40:1046 (2018) (listing above diseases as debilitating 
medical conditions eligible for treatment with recommended medical marijuana). 
 41. See supra note 18. 
 42. MARIJUANA POLICY PROJECT, STATE-BY-STATE MEDICAL MARIJUANA 
LAWS (2015), https://www.scribd.com/document/264980279/State-by-State-
Laws-Report-2015 [https://perma.cc/ATF4-2BCV]. 
 43. MASS. GEN. LAWS ch. 94C app., § 1-4 (West 2006 & Supp. 2014); MICH. 
COMP. LAWS ANN. § 333.26424 (West 2001 & Supp. 2017); see also ALASKA 
STAT. § 17.37.030 (2012); CAL. HEALTH & SAFETY CODE § 11362.5(b)(1)(B) 
(West 2007 & Supp. 2016); MONT. CODE ANN. § 50-46-319 (2016); N.J. STAT. 
ANN. § 24:61-2 (West 2007 & Supp. 2017); N.M. STAT. ANN. § 26-2B-4 (2007 
& Supp. 2017); OR. REV. STAT. § 475.300 (2016); R.I. GEN. LAWS § 21-28.6-4 




Nine states explicitly protect medical marijuana users from employment 
discrimination based on a positive drug test.44 A stark contrast exists 
between the planes of federal and state law on this issue, however, because 
although medical marijuana use is legal under the laws of the individual 
states that have provided for such use, it remains illegal under the CSA.45  
C. Disparity in Federal and State Law Governing Marijuana Use 
The federal government has recognized the disparity between state 
law’s allowance of medical marijuana use and federal law’s wholesale ban 
on marijuana, and it has taken steps to address the differences. Both the 
executive and legislative branches have attempted to bridge the divide 
between the CSA and state decriminalization efforts. The goal of these 
steps is to permit the states the ability to regulate marijuana but maintain 
that the federal government, through the CSA, has the final say on the 
legality of any marijuana use. In 2017, the change in administration 
upended the status quo, bringing into question whether the federal 
government’s next move will be to enforce the CSA in spite of state 
decriminalization efforts.46 
1. Executive Agency Actions 
During the Obama Administration and up until January 2018, 
executive agencies dealt with the tension between state and federal law by 
directing federal prosecutors to follow a policy of non-interference with 
state programs that allowed for the regulated use of marijuana.47 This 
                                                                                                             
(2002 & Supp. 2013); WASH. REV. CODE § 69.5 1A.040 (West 2007 & Supp. 
2017); see also MARIJUANA POLICY PROJECT, supra note 42. 
 44. See supra note 21. 
 45. See 21 U.S.C. § 812 (2012). 
 46. In 2017, Donald J. Trump was inaugurated as President of the United States 
and began shifting the policies of the Executive Branch to the right through his 
appointments. The most significant administrative change was the appointment of 
Jefferson Beauregard Sessions, a stringent opponent of marijuana legalization, as 
Attorney General. See Memorandum from Jefferson B. Sessions, III, U.S. Attorney 
General, to All U.S. Attorneys (Jan. 4, 2018), https://www.justice.gov/opa/press-
release/file/1022196/download [https://perma.cc/6LYE-N8EV] [hereinafter 
“Sessions Memo”] (rescinding previous nationwide guidance specific to marijuana 
enforcement, including the Ogden and Cole Memoranda). 
 47. See Memorandum from David W. Ogden, Deputy Attorney General, to 
Selected U.S. Attorneys (Oct. 19, 2009), https://www.justice.gov/sites/default 
/files/opa/legacy/2009/10/19/medical-marijuana.pdf [https://perma.cc/R4GM-DD 
RM] [hereinafter “Ogden Memo”] (establishing guidelines on investigations and 




policy was set forth in guidance documents and generally recommended 
that federal prosecutors not disrupt state medical marijuana regulation by 
single-mindedly enforcing CSA prohibitions.48  
In 2009, Deputy Attorney General David Ogden released a memo 
(“Ogden Memo”) discouraging federal prosecution of individuals using 
marijuana for medical purposes in accordance with state law, reasoning 
that such prosecutions would be a waste of federal resources.49 Although 
the CSA entirely prohibits the cultivation and possession of marijuana, the 
Ogden Memo stated that federal prosecutors should focus on illegal drug 
trafficking networks rather than organizations acting in compliance with 
state laws.50  
In 2011, Deputy Attorney General James Cole reaffirmed the policy 
stated in the Ogden Memo.51 Cole then directed prosecutors to take an 
even more deferential stance to the states in 2013, issuing his own memo 
(“Cole Memo”) guiding U.S. Attorneys by stating that the Department of 
Justice (“DOJ”) would not prioritize enforcement of federal marijuana 
laws in states with laws allowing use of marijuana, so long as the states 
possess “strong and effective regulatory and enforcement systems.”52 The 
Ogden Memo emphasized that state decriminalization could not prevent 
federal enforcement of the CSA, sending contradictory messages of 
restraint and readiness regarding state-sanctioned marijuana production.53 
The Cole Memo guided federal prosecutors towards further reliance on 
state regulation of medical marijuana, suggesting that federal prosecution 
would be appropriate only where local authorities were not applying state 
                                                                                                             
prosecutions in states authorizing the medical use of marijuana); see also 
Memorandum from James M. Cole, Deputy U.S. Attorney General, to All U.S. 
Attorneys (Aug. 29, 2013), http://www.justice.gov/iso/opa/resources/3052013829 
132756857467.pdf [https://perma.cc/63SW-753T] [hereinafter “Cole 2013 Memo”] 
(setting forth guidance regarding marijuana enforcement). 
 48. Supra note 47. 
 49. See Ogden Memo, supra note 47. 
 50. See id. (listing indicia such as unlawful use of firearms, violence, and 
financial activities inconsistent with state law as signs that federal prosecutors 
may want to investigate and prosecute a particular case involving marijuana). 
 51. Memorandum from James M. Cole, Deputy U.S. Attorney General, to 
U.S. Attorneys (June 29, 2011), https://www.justice.gov/sites/default/files/oip 
/legacy/2014/07/23/dag-guidance-2011-for-medical-marijuana-use.pdf [https:// 
perma.cc/94SF-N4SC]. 
 52. See Cole 2013 Memo, supra note 47. 
 53. See Ogden Memo, supra note 47 (stating that prosecutors are not 
precluded from investigating and prosecuting actions undertaken in compliance 
with state law). 




regulations.54 The memoranda from Ogden and Cole suggested federal 
prosecutors should not interfere with state marijuana decriminalization 
and regulation, but maintained prosecutors’ power to enforce the CSA 
regardless of state law.55 
The policy of non-interference stated in the Ogden and Cole Memos 
was not legislation, however, executive guidance documents are subject to 
change. The early days of January 2018 brought such a change, as 
Attorney General Jeff Sessions rescinded all previous guidance documents 
regarding the enforcement of marijuana’s CSA prohibition.56 The actual 
effects of this change remain unknown at this point, although the question 
remains whether Attorney General Sessions’s memo rescinding the 
Obama-era stance of noninterference will have any major impact in the 
near future.57 Further, Sessions’s resignation from office adds further 
uncertainty as any new Attorney General might make further changes to 
DOJ policy. Although the rescission of the Ogden and Cole Memos pulls 
back from a message of deference to state regulation, thereby giving 
federal prosecutors more freedom to pursue violators of the CSA and 
remain in line with the DOJ, it is unlikely that the government would target 
organizations and individuals acting within state medical marijuana 
guidelines because Attorney General Session’s memo did not explicitly 
encourage such targeting of state-compliant organizations.58 Thus, while 
the Ogden and Cole Memos are no longer guiding forces, the common 
sense rationale behind them continues: namely, that DOJ funds are better 
spent pursuing illicit drug trafficking connected to violence rather than 
organized groups acting according to state regulations.  
Sessions’s memo, still in effect unless and until the next Attorney 
General rescinds it, supports the belief that the rescission of earlier 
guidance documents will not greatly impact the prosecutorial discretion 
that has been exercised regarding medical marijuana, as the memo 
instructs federal prosecutors to follow the principles set forth in the U.S. 
                                                                                                             
 54. See Cole 2013 Memo, supra note 47. 
 55. See id.; see also Ogden Memo, supra note 47. 
 56. See Sessions Memo, supra note 46. 
 57. See Thomas Fuller, California Defiant in face of Federal Move to Get 
Tough on Marijuana, N.Y. TIMES (Jan. 4, 2018), https://www.nytimes.com 
/2018/01/04/us/california-defiant-in-face-of-federal-move-to-get-tough-on-mari  
juana.html?mtrref=query.nytimes.com [https://perma.cc/XEB4-KEHL]; see also 
The New York Times Editorial Board, Editorial, Jeff Session’s Endless War on 
Marijuana, N.Y. TIMES (Jan. 7, 2018), https://www.nytimes.com/2018/01/07/ 
opinion/jeff-sessionss-war-marijuana.html [https://perma.cc/X3Q4-5L77]. 
 58. See Sessions Memo, supra note 46. 




Attorneys’ Manual.59 Whether such a prosecution would be an effective 
and efficient use of resources is among the principles the government uses 
when determining whether to prosecute a case.60 How the DOJ will 
proceed from this point, however, is not clear. 
2. Congressional Budget Modifications 
In addition to executive action, Congress has also taken steps to ensure 
that federal agents respect state programs decriminalizing marijuana.61 In 
2014, the government included a provision preventing the DOJ from using 
funds to interfere with state medical marijuana programs in the 
Congressional budget.62 Congress passed this provision every subsequent 
year as well.63 The lack of funds available to federal prosecutors because 
of this budgetary restriction has led to the dismissal of at least one case.64  
The tension between the federal CSA and the state medical marijuana 
decriminalization efforts persists.65 The legislative budgetary restrictions 
remain in place as of now, since Congress included this provision in the 
most recent spending bill in March 2018.66 The rescission of the Cole and 
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Ogden Memos seems to demonstrate the change in the DOJ’s perception 
of state decriminalization, intensifying the uneasiness that defines the 
coexistence of federal and state marijuana laws. Despite marijuana’s 
federal illegality, analysis of preemption doctrine and state legislative 
power demonstrates that states have the power to decriminalize the use of 
medical marijuana, and further, the ability to provide valid employment 
protections for state citizens wrongfully terminated because of marijuana 
use. 
II. THE CONFLICT OF FEDERAL AND STATE MARIJUANA LAW IN 
EMPLOYMENT LAW 
The simultaneous wholesale prohibition of marijuana under federal 
law and decriminalization under state law creates significant conflict in all 
areas of the law, including employment law. The illegality of marijuana 
under the CSA prevents medical marijuana users from protection under 
the ADA, the federal statute protecting individuals with disabilities from 
discrimination.67 The ADA does not cover individuals engaged in the use 
of illegal drugs, and marijuana’s status as a Schedule I substance under the 
CSA places it within that exception.68  
The ADA provides the most significant means of legal recourse 
available to disabled individuals who encounter discrimination at work 
because of their disabilities.69 If a person can perform the required tasks of 
a job with a reasonable accommodation for his disability and that 
reasonable accommodation does not cause undue hardship to the 
employer, the ADA forbids discrimination against that person on the basis 
of his disability.70 The statutes that comprise the ADA prohibit not only 
discrimination based on a disability itself, but also forbids refusal to make 
reasonable accommodations for the worker’s disability.71 This broad 
proscription of discriminatory practices provides protection from 
discrimination-based adverse employment actions for employees who 
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have a disability, creating a cause of action for those whose disabilities 
have not been reasonably accommodated.72  
To make a prima facie case under the ADA, however, a claimant must 
be a qualified individual, and the ADA specifically excludes employees 
who use illegal substances under the CSA from the definition of a qualified 
individual.73 Accordingly, the ADA is useless for employees who are 
terminated based on their use of medical marijuana, since those individuals 
are not qualified to sue under the statute.74 
Any recourse available to such employees therefore, can only exist 
within state law.75 Until recently, states’ attempts to provide employment 
protection to medical marijuana users were routinely held to be invalid in 
state courts. The primary rationales for these holdings were based on a 
preemption theory or on statutory construction.76  
A. The Lone Finding of Preemption: Emerald Steel  
The United States Constitution states that federal law is the “supreme 
Law of the Land.”77 If a federal law conflicts with a state law, the federal 
law preempts the conflicting state law and renders it invalid.78 Whether the 
CSA conflicts with and preempts state decriminalization laws is a central 
and unanswered question.79 If the CSA preempts state statutes 
decriminalizing medical marijuana, the state laws and protections they 
provide would be without effect and prosecution for medical marijuana 
use would be entirely at the whim of the federal government.80 The CSA’s 
prohibition of marijuana as a Schedule I substance seems to stand in direct 
conflict with state laws decriminalizing the drug, but the language of the 
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CSA itself demonstrates no direct conflict exists when states decriminalize 
marijuana.81  
Four types of preemption exist: express; field; conflict; and obstacle.82 
Express preemption only exists when Congress includes an explicit 
provision in the federal statute stating an intention to preempt any state or 
local laws.83 Field preemption is when the statute or statutory scheme 
clearly states Congress intended to “occupy the field” and leave no room 
for state or local legislatures to craft laws within that area.84 Neither of 
these forms of preemption applies in the context of marijuana regulation.85 
The CSA has no explicit preemption clause, demonstrating that express 
preemption does not affect marijuana regulation.86  
The CSA does, however, have an explicit provision that states that it 
is not meant to “occupy the field” of drug legislation.87 That provision 
instead says that the CSA does not preempt any state law unless “there is 
a positive conflict” between the two, such that they cannot exist 
simultaneously.88 This “positive conflict” language demonstrates that the 
CSA can only overrule state law regarding decriminalization of marijuana 
through the theories of either conflict or obstacle preemption. 
Direct conflict preemption only occurs if it is impossible to obey both 
federal and state laws at the same time.89 This standard is very narrow, and 
one can meet it only when a state law requires an act contrary to a federal 
law.90 Neither decriminalization of medical marijuana nor employment 
protections for medical marijuana users under state law would conflict 
with the CSA directly, since such provisions do not require possession, 
use, or distribution of marijuana, but only allow it.91 Therefore, obstacle 
preemption is the only type of preemption that could potentially apply. 
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Obstacle preemption applies if the state law at issue is inconsistent with 
the purposes and objectives of federal law.92  
Only one court has found a state law regulating medical marijuana to 
be preempted by the CSA using an obstacle preemption analysis.93 In 
Emerald Steel Fabricators, Inc. v. Bureau of Labor & Industry, a 
temporary employee used medical marijuana daily to treat his anxiety and 
nausea, a permitted “debilitating medical condition” under the Oregon 
Medical Marijuana Act.94 When the opportunity to become a permanent 
employee arose, the employee informed his supervisor of his medical 
marijuana use and provided his registry card to show that Oregon state law 
sanctioned his use.95 The employer promptly terminated the employee, and 
the employee filed a complaint for discrimination against the employer.96 
The Supreme Court of Oregon found that the state law did not just 
decriminalize the use of medical marijuana, but affirmatively authorized 
its use.97 The state law therefore stood as an obstacle to the enforcement 
of the CSA, such that the CSA preempted the state law.98 
Emerald Steel is the only decision in which a state supreme court found 
that the CSA preempts state laws providing protection for medical 
marijuana users, and several contemporaries have criticized the decision.99 
Obstacle preemption carries a strong presumption against preemption if the 
federal law lies within an area the state traditionally governs.100 This 
presumption against obstacle preemption should have led the Oregon 
Supreme Court to find that the CSA did not preempt the state law protecting 
medical marijuana users, as evidenced by other courts’ determinations that 
obstacle preemption does not apply to state laws regulating medical 
marijuana.101 The decision in Emerald Steel is an anomaly, and other courts 
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should find state laws that provide employment protection for medical 
marijuana users valid and find that the CSA does not preempt them.102  
B. The Significance of Statutory Language: Coats 
Although preemption does not preclude states from protecting medical 
marijuana users from employment discrimination, several cases have shown 
that state courts may strike down ambiguous statutes providing medical 
marijuana users protection.103 The tension between the CSA and state medical 
marijuana statutes is the cause of the ambiguity problem; this tension renders 
the word “lawful” ambiguous in state medical marijuana statutes.104 For 
example, in Coats v. Dish Network, L.L.C., an employer terminated an 
employee who used medical marijuana at home during nonworking hours.105 
The employee sought a claim for wrongful termination, alleging that the 
reason for his termination was his use of medical marijuana, a use in accord 
with the state law of Colorado.106 Colorado’s wrongful termination statute 
forbade employers from terminating employees for engaging in any “lawful 
activity” outside of work.107  
The employee in Coats argued that the word “lawful” in the context 
of the statute meant lawful in accordance with Colorado state law.108 The 
Colorado Supreme Court determined instead that “lawful” meant an 
activity that complies with both state and federal law.109 Because 
marijuana use remains illegal under federal law, the Colorado Supreme 
Court found that employees’ wrongful termination protection could not 
extend to individuals using medical marijuana.110 An employee could only 
have a claim for wrongful termination if the activity for which he was 
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terminated was lawful under both state and federal law.111 Statutory 
construction of the word “lawful” created a bar for employees seeking 
protection under Colorado statutes for their medical marijuana use.112 
Coats and similar jurisprudence show that the tension between federal and 
state law regarding marijuana regulation requires precise statutory 
language in order to survive judicial scrutiny and successfully provide 
employment protections for medical marijuana users. 
Prior to 2017, no court found a claim enforceable for employer 
discrimination based on an employee’s use of state-sanctioned medical 
marijuana.113 In the summer of 2017, however, two state court decisions 
allowed claims for wrongful termination and discrimination to proceed.114 
These two cases, Barbuto v. Advantage Sales and Noffsinger v. SSC Niantic 
Operating Company, L.L.C., upheld two different types of statutory 
protection for medical marijuana users, demonstrating viable paths for 
protecting medical marijuana users from employment discrimination.115 The 
first of these cases, Barbuto, found that the Massachusetts medical marijuana 
laws did not themselves create a cause of action for discrimination, but did 
provide a claim under a state handicap discrimination law.116 
C. The Use of Broad Protection of Rights as a Bridge: Barbuto 
In July of 2017, the Massachusetts Supreme Court became the first 
state supreme court to find that a claim for employment discrimination 
based on an individual’s state-sanctioned use of medical marijuana could 
move forward.117 The statute at issue stated “[a]ny person [qualifying for 
use of medical marijuana] shall not be penalized under Massachusetts law 
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in any manner, or denied any right or privilege, for such actions.”118 In 
Barbuto v. Advantage Sales, the Massachusetts Supreme Court found this 
broad provision of the Massachusetts Medical Marijuana Act to allow an 
individual to maintain a claim of handicap discrimination under another 
state statute.119 The Court refused to find that marijuana’s illegality under 
the CSA made its medical use a per se unreasonable accommodation under 
the state handicap statute.120  
The Massachusetts Supreme Court did not find that the medical 
marijuana statutes themselves created a private cause of action.121 Instead, 
a state anti-handicap discrimination law preserved the plaintiff’s claim.122 
The medical marijuana statute, by not hinging employment discrimination 
on the legality of the substance, avoided any possible ambiguity that might 
derail the purpose of the law.123 The Massachusetts Legislature crafted a 
statute that protected medical marijuana users from civil penalty, creating 
state-level protections that would not be invalidated because of the CSA’s 
prohibition of marijuana. Although the medical marijuana statute was 
insufficient on its own to create a cause of action for the affected 
employee, it served as a bridge to other anti-discrimination statutes.124 
Unlike the Massachusetts statute, the Connecticut federal district court 
found the Connecticut provision at issue in Noffsinger to create its own 
cause of action and serve as an independent vehicle for anti-discrimination 
protections.125  
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D. The Creation of Private Rights of Action: Noffsinger  
In contrast to Barbuto, the United States District Court for the District 
of Connecticut found that a specific anti-discrimination provision included 
in the Connecticut Palliative Use of Marijuana Act provided a private 
cause of action for employees terminated for the use of medical 
marijuana.126 The statute says in pertinent part, “No employer may refuse 
to hire a person or may discharge, penalize or threaten an employee solely 
on the basis of such person’s or employee’s status as a qualifying 
patient.”127 The district court found that the CSA did not preempt the 
provision, since no tension between the two laws rose to the level of 
conflict required for obstacle preemption.128 The CSA does not explicitly 
prohibit employers from hiring applicants that may be using illegal 
substances, meaning that the Connecticut statute was no obstacle to the 
CSA and therefore was not preempted.129 Additionally, the federal court 
found that the provision of Connecticut law did not authorize use of illegal 
substances in the workplace, preventing ADA preemption.130 
Coming fast on the heels of Barbuto, Noffsinger was another case in 
which a federal court recognized that states were able to protect employees 
using medical marijuana without the CSA preempting protection.131 Further, 
the statute in Noffsinger did not need another statute to function as an 
employment protection.132 The Connecticut Legislature had successfully 
written a law that filled the gap in employment protection the ADA’s 
exclusion of CSA Schedule I substances caused, and created a means of 
suing an employer for discriminatory actions based on an employee’s 
legitimate use of medical marijuana.133 The Connecticut federal court 
determined that the inclusion of a specific anti-discrimination provision 
created an implied private cause of action under the medical marijuana 
statute itself.134 Louisiana, unlike Massachusetts and Connecticut, has no 
statute that could serve as a means of protecting citizens that use medical 
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marijuana. This is a gap in the law that the Louisiana Legislature must fill 
to allow citizens access to the healthcare they need.135  
III. LOUISIANA’S INCOMPLETE MEDICAL MARIJUANA STATUTES 
Louisiana’s program for medical marijuana access exists through two 
statutes: Louisiana Revised Statutes § 40:966, which exempts participants 
in the medical marijuana program from criminal prosecution; and Louisiana 
Revised Statutes § 40:1046, which establishes the means of production, 
recommendation, and distribution of medical marijuana for citizens with a 
qualifying debilitating disease.136 Unlike Massachusetts’s medical 
marijuana statutes, Louisiana’s two statutes do not include a provision 
ensuring that any qualified user of medical marijuana “shall not be penalized 
under [Louisiana] law in any manner, or denied any right or privilege, for 
[such use of medical marijuana].”137 The Louisiana statutes also do not 
provide an explicit employment anti-discrimination provision like the one 
in Connecticut’s medical marijuana statute.138 
The two statutes that comprise Louisiana’s medical marijuana 
program lack any form of protection for employees eligible to use medical 
marijuana.139 Without modification, an individual suffering from one of 
the debilitating diseases that qualifies her for medical marijuana use will 
have a serious decision to make. She can seek effective medication for his 
illness by fulfilling a recommendation for medical marijuana, but in so 
doing risk losing her job. Alternatively, she can continue to suffer in order 
to maintain gainful employment. To protect Louisiana citizens from being 
forced to choose between their health and their livelihood, the Louisiana 
Legislature must modify the current medical marijuana statutes to include 
an anti-discrimination provision. 
IV. FINDING A WAY THROUGH THE WEEDS 
If the United States Congress would recognize the medical uses of 
marijuana and reschedule it under the CSA, Louisiana’s government 
would not need to act. Federal anti-discrimination protections under the 
ADA would become available to employees whose doctors recommend 
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medical marijuana, rendering the need for state law protections moot.140 
Such Congressional action seems unlikely considering the current political 
climate and lack of bipartisan cooperation.141 The response to former 
Attorney General Jeff Session’s rescission of the Ogden and Cole memos 
may signify changing times, especially because 33 states have legalized 
marijuana.142 Barring a surprising Congressional effort to amend the CSA, 
the onus falls on Louisiana to craft legislation creating statutory protections 
for employees using medical marijuana. 
A. Louisiana Should Adopt an Explicit Employment Anti-Discrimination 
Provision  
With the CSA as it currently stands, only state law can protect 
employees who suffer debilitating conditions that entitle them to use 
medical marijuana under Louisiana law. To fill the current gap in its medical 
marijuana statutes, Louisiana should look to states with employment 
protections for medical marijuana users that have survived judicial scrutiny.  
Barbuto and Noffsinger evidence that the CSA will not necessarily 
preempt medical marijuana statutes designed to protect employees from 
wrongful termination and discrimination based on their marijuana use.143 
In Barbuto, the Massachusetts Supreme Court found that a Massachusetts 
provision forbidding the imposition of civil penalties because of a citizen’s 
medical marijuana use could act as a bridge to other anti-discrimination 
statutes.144 The court invoked a state handicap law to effectuate 
employment protection, marking the Massachusetts statutory scheme as 
                                                                                                             
 140. See 42 U.S.C. § 12114 (2012). If the federal government rescheduled 
marijuana under the CSA it would no longer be an illegal drug, allowing users of 
medical marijuana to fall within the definition of qualified disabled employee under 
the ADA. Additionally, Louisiana doctors would be able to accurately term their 
actions as “prescribing” marijuana rather than “recommending” it. See supra note 3.  
 141. See Jennifer Steinhauer, With Few Wins in Congress Republicans Agree 
on Need to Agree, N.Y. TIMES (Aug. 4, 2017), https://www.nytimes.com/2017/08 
/04/us/politics/congress-republican-agree-unity.html [https://perma.cc/TD38-G3 
W9]; see also The New York Times Editorial Board, Editorial, Canada, but Not 
Jeff Sessions, Moves Boldly on Marijuana, N.Y. TIMES (Apr. 15, 2017), https:// 
www.nytimes.com/2017/04/15/opinion/sunday/canada-but-not-jeff-sessions-move 
s-boldly-on-marijuana.html [https://perma.cc/M7HB-F2RN]. 
 142. See The New York Times Editorial Board, supra note 57 (noting the 
negative responses of Republican and Democrat leaders on Capitol Hill).  
 143. See Barbuto v. Advantage Sale & Mktg., LLC, 78 N.E.3d 37 (2017); 
Noffsinger v. SSC Niantic Operating Co. LLC, 273 F. Supp. 3d 326 (D. Conn. 2017). 
 144. Barbuto, 78 N.E.3d 37. 




functional, but not ideal.145 In contrast, Connecticut’s Palliative Use of 
Marijuana Act includes an express employment anti-discrimination 
provision, creating a private cause of action for employees who have been 
victims of discrimination.146 A similarly explicit anti-discrimination 
provision is the best solution to fill Louisiana’s current gap in medical 
marijuana legislation, as it would create a clear and unambiguous means 
of suing for employment discrimination under state law. 
B. A Model Statutory Provision that Balances Employee and Employer 
Needs 
The model provision below is based on Connecticut law and 
incorporates protection from discrimination into Louisiana Revised 
Statutes § 40:1046. It uses the definitions already found in the Louisiana 
medical marijuana statutes to create a clear and unambiguous protection 
from employment discrimination on the basis of medical marijuana use:147 
No employer may refuse to hire a person or may discharge, 
penalize, or threaten an employee solely on the basis of such 
person’s or employee’s status as a patient suffering from a 
debilitating medical condition as defined in §1046(A)(2)(a) and 
recommended medical marijuana as defined in §1046(A)(3). 
 
Nothing in this subdivision shall restrict an employer’s ability to 
prohibit the use of intoxicating substances during work hours or 
restrict an employer’s ability to discipline an employee for being 
under the influence of intoxicating substances during work hours. 
An explicit employment anti-discrimination provision, such as the one 
above, will eliminate any federal law interference, creating a means of suing 
for discrimination beyond any claims of CSA preemption.148 Although the 
broad protection of the Massachusetts Medical Marijuana Act also resulted 
in a possible solution to the lack of employment protection for medical 
marijuana users, it did not create a cause of action within the medical 
marijuana statutes, but instead created a right to sue under the state’s anti-
handicap discrimination statutes.149 A broad statement that citizens’ rights 
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will not be abridged because of medical marijuana use could create a 
loophole for employers to argue that the ADA applies and renders any 
attempted protection null because of marijuana’s illegality under the CSA, 
thereby making it an ineffective solution to the problem in Louisiana law.150 
Louisiana should therefore include an anti-discrimination provision, similar 
to that of Connecticut, in Louisiana’s medical marijuana statutes. Such a 
provision will create an unambiguous means of employment protection that 
will exist wholly within state law and that the CSA will not affect. Such a 
provision might also face some opposition from employers around the state, 
who fear a parade of impaired workers that they are prevented from 
replacing with more conscientious staff. 
Louisiana employers might oppose such an anti-discrimination provision 
in the belief that it would allow workers to come to work incapacitated. If 
Louisiana were to adopt the Connecticut medical marijuana anti-discrimination 
provision as its model, however, these fears would be unfounded.151 The 
protections granted to employees would not force employers to accept 
lackluster or unprofessional work behavior from individuals.152 Employees 
would not be allowed to abuse the protected use of medical marijuana; instead, 
the state would strike a balance between necessary protections for employees 
and freedom to conduct business for employers.153 
CONCLUSION 
Louisiana’s provisions governing the regulation of medical marijuana 
have yet to go into effect, but the state is steadily progressing towards the 
implementation of a statutory medical marijuana program.154 Although 
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gaps in the statutory scheme currently exist, the Louisiana Legislature can 
fill these holes and protect employees with debilitating medical conditions 
from discrimination.155 Marijuana is entirely illicit under federal law, but an 
anti-discrimination provision modeled off of the version in the Connecticut 
Palliative Use of Marijuana Act would achieve the goal of protecting 
employees from discrimination and avoiding federal preemption.156  
The provision would create a private state law cause of action under 
which employees could sue for protection against discrimination.157 The 
provision would simultaneously preserve the right of employers to 
discipline workers who come to the workplace intoxicated, no matter their 
status as medical marijuana patients.158 Earlier employee attempts to seek 
protection from employment discrimination under state medical marijuana 
decriminalization laws have failed because of either statutory construction 
or preemption. The federal court’s upholding of the Connecticut provision, 
however, demonstrates its viability as a means of protecting those workers 
who would otherwise have to choose between their health and their jobs.159 
The Louisiana Legislature has taken a huge step forward by legalizing 
medical marijuana, and it is a step that will improve the lives of suffering 
citizens. But the Legislature must now look forward and fill the remaining 
gaps in citizen protections before the medical marijuana program is fully 
implemented, in order to give the most complete benefit to Louisiana’s 
citizens. Louisiana should learn from its sister states and draft legislation 
to protect individuals who use medical marijuana for relief from symptoms 
of chronic illnesses. Citizens should not have to weigh their health and 
well-being against their hopes of gainful employment.  
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